NASDAQ:SLRN Acelyrin (SLRN) Stock Price, News & Analysis → 😱 This phenomenon is smashing regular market gains (From MillPub) (Ad) Free SLRN Stock Alerts $4.25 +0.07 (+1.67%) (As of 05/1/2024 ET) Add Compare Share Share Today's Range$4.19▼$4.3850-Day Range$4.18▼$8.6352-Week Range$4.14▼$29.88Volume1.14 million shsAverage Volume1.20 million shsMarket Capitalization$420.37 millionP/E RatioN/ADividend YieldN/APrice Target$23.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Acelyrin alerts: Email Address Acelyrin MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.57 Rating ScoreUpside/Downside456.9% Upside$23.67 Price TargetShort InterestBearish12.80% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingSelling Shares$119,328 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($4.18) to ($4.69) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.33 out of 5 starsMedical Sector737th out of 927 stocksPharmaceutical Preparations Industry332nd out of 420 stocks 3.3 Analyst's Opinion Consensus RatingAcelyrin has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageAcelyrin has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted12.80% of the float of Acelyrin has been sold short.Short Interest Ratio / Days to CoverAcelyrin has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Acelyrin has recently decreased by 1.26%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAcelyrin does not currently pay a dividend.Dividend GrowthAcelyrin does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SLRN. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Acelyrin this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for SLRN on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Acelyrin to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acelyrin insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $119,328.00 in company stock.Percentage Held by Institutions87.31% of the stock of Acelyrin is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Acelyrin are expected to decrease in the coming year, from ($4.18) to ($4.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acelyrin is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acelyrin is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcelyrin has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe biggest energy story ever? Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie…For the full story, click here. About Acelyrin Stock (NASDAQ:SLRN)Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.Read More SLRN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SLRN Stock News HeadlinesMay 1, 2024 | americanbankingnews.comAcelyrin (SLRN) & The Competition Financial AnalysisApril 29, 2024 | globenewswire.comACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024May 1, 2024 | Porter & Company (Ad)The biggest energy story ever? Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie…April 1, 2024 | msn.comStocks Pressured as Bond Yields Jump on Strength in US ManufacturingApril 1, 2024 | markets.businessinsider.comACELYRIN, INC.: Promising Clinical Trials and Market Opportunity Justify Buy RatingMarch 28, 2024 | investorplace.comSLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023March 28, 2024 | finance.yahoo.comACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent HighlightsMarch 28, 2024 | globenewswire.comACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent HighlightsMay 1, 2024 | Porter & Company (Ad)The biggest energy story ever? Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie…March 20, 2024 | markets.businessinsider.comBuy Rating on ACELYRIN, INC.: Promising Clinical Prospects for Novel TED Therapy LonigutamabMarch 20, 2024 | markets.businessinsider.comAcelyrin Announces Positive Phase 1/2 Data For Lonigutamab In Thyroid Eye Disease; Stock UpMarch 20, 2024 | msn.comInvestors Cheer Acelyrin's Stock, Its Second Lead Candidate Shows Clinical Benefit In Thyroid Eye Disease PatientsMarch 20, 2024 | finance.yahoo.comACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye DiseaseMarch 18, 2024 | finance.yahoo.comSLRN Apr 2024 2.500 putMarch 12, 2024 | seekingalpha.comAcelyrin: Analyzing Its Recovery And Potential In Psoriatic ArthritisMarch 12, 2024 | markets.businessinsider.comHold Rating Affirmed for ACELYRIN, INC. as Izokibep Faces Competitive Hurdles and Safety ConcernsMarch 11, 2024 | marketwatch.comAcelyrin Stock Climbs 10% on Positive Results for Arthritis TreatmentMarch 11, 2024 | msn.comAcelyrin's Lead Drug Candidate Hits Primary Goal In Late-Stage Psoriatic Arthritis StudyMarch 11, 2024 | markets.businessinsider.comAcelyrin's Phase2b/3 Trial Of Izokibep In Psoriatic Arthritis Meets Primary EndpointMarch 11, 2024 | globenewswire.comACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic ArthritisMarch 11, 2024 | globenewswire.comACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for PatientsFebruary 15, 2024 | finance.yahoo.comACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate CommunicationsFebruary 15, 2024 | globenewswire.comACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate CommunicationsFebruary 9, 2024 | markets.businessinsider.comHold Rating on ACELYRIN, INC. Amidst Clinical Trials and Risk/Reward AnalysisJanuary 16, 2024 | markets.businessinsider.comAcelyrin Final Deadline AlertJanuary 12, 2024 | stockhouse.comUpcoming SLRN Deadline: Bronstein, Gewirtz & Grossman LLC Reminds ACELYRIN, Inc. Investors with Substantial Losses to Contact the Firm!January 12, 2024 | stockhouse.comDEADLINE MONDAY ALERT: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses of $100,000 to Contact the FirmSee More Headlines Receive SLRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acelyrin and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today5/01/2024Next Earnings (Confirmed)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SLRN CUSIPN/A CIK1962918 Webwww.acelyrin.com Phone805-730-0360FaxN/AEmployees135Year FoundedN/APrice Target and Rating Average Stock Price Target$23.67 High Stock Price Target$68.00 Low Stock Price Target$8.00 Potential Upside/Downside+456.9%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($10.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-381,640,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-50.56% Return on Assets-38.65% Debt Debt-to-Equity RatioN/A Current Ratio8.65 Quick Ratio8.65 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.74 per share Price / Book0.63Miscellaneous Outstanding Shares98,910,000Free FloatN/AMarket Cap$420.37 million OptionableOptionable BetaN/A 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Shao-Lee Lin M.D. (Age 56)Ph.D., Co-Founder, CEO & Director Comp: $846.25kMs. Melanie Gloria B.S.N. (Age 46)Chief Operating Officer Comp: $672.58kMr. Gilbert M. Labrucherie J.D. (Age 52)Chief Financial Officer, Principal Financial Officer & principal accounting officer Ms. Mina Kim (Age 50)Chief Legal & Administrative Officer Mr. Tyler MarciniakHead of Investor Relations & CommunicationsMr. Ron Oyston (Age 54)Chief People Officer Dr. Paul M. Peloso M.D. (Age 66)M.Sc., Chief Medical Officer Ms. Suzy Buckhalter CPASenior Director of Finance & AccountingMr. Kenneth A. Lock (Age 50)Chief Commercial Officer Dr. Shephard Mpofu M.D.Senior Vice President of DevelopmentMore ExecutivesKey CompetitorsEntrada TherapeuticsNASDAQ:TRDAAnnexonNASDAQ:ANNXTravere TherapeuticsNASDAQ:TVTXLarimar TherapeuticsNASDAQ:LRMRKalVista PharmaceuticalsNASDAQ:KALVView All CompetitorsInsiders & InstitutionsChina Universal Asset Management Co. Ltd.Bought 7,459 shares on 4/29/2024Ownership: 0.019%Shao-Lee LinSold 15,701 sharesTotal: $119,327.60 ($7.60/share)Superstring Capital Management LPBought 356,924 shares on 2/14/2024Ownership: 0.367%Sectoral Asset Management Inc.Bought 325,549 shares on 2/14/2024Ownership: 0.334%Point72 Europe London LLPBought 122,971 shares on 2/14/2024Ownership: 0.126%View All Insider TransactionsView All Institutional Transactions SLRN Stock Analysis - Frequently Asked Questions Should I buy or sell Acelyrin stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acelyrin in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SLRN shares. View SLRN analyst ratings or view top-rated stocks. What is Acelyrin's stock price target for 2024? 7 analysts have issued 1 year target prices for Acelyrin's shares. Their SLRN share price targets range from $8.00 to $68.00. On average, they expect the company's stock price to reach $23.67 in the next twelve months. This suggests a possible upside of 456.9% from the stock's current price. View analysts price targets for SLRN or view top-rated stocks among Wall Street analysts. How have SLRN shares performed in 2024? Acelyrin's stock was trading at $7.46 at the beginning of the year. Since then, SLRN shares have decreased by 43.0% and is now trading at $4.25. View the best growth stocks for 2024 here. When is Acelyrin's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our SLRN earnings forecast. How can I listen to Acelyrin's earnings call? Acelyrin will be holding an earnings conference call on Monday, May 13th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Acelyrin's earnings last quarter? Acelyrin, Inc. (NASDAQ:SLRN) announced its quarterly earnings data on Thursday, March, 28th. The company reported ($0.75) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.25. When did Acelyrin IPO? Acelyrin (SLRN) raised $540 million in an initial public offering (IPO) on Friday, May 5th 2023. The company issued 30,000,000 shares at a price of $18.00 per share. Who are Acelyrin's major shareholders? Acelyrin's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include China Universal Asset Management Co. Ltd. (0.02%). Insiders that own company stock include Beth C Seidenberg, Biopartners Fund Ii Westlake, Mardi Dier, Ronald Oyston and Shao-Lee Lin. View institutional ownership trends. How do I buy shares of Acelyrin? Shares of SLRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SLRN) was last updated on 5/1/2024 by MarketBeat.com Staff From Our PartnersElon’s New Device is About to Shock the WorldInvestorPlaceThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market Insiders😱 This phenomenon is smashing regular market gainsMillPubYour bank is lying to you.MyBankTrackerDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Nvidia. This is the future of AIPorter & CompanyBiden out June 13; Kamala won’t replace him?Paradigm PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acelyrin, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
